Page 65 - e-CPG-SLE-8_5_24

Management of Systemic Lupus Erythematosus

Life, International Systemic Lupus Erythematosus Cohort. Arthritis Care Res
(Hoboken). 2015;67(8):1180-1185.
37. Selvananda S, Kan SL. Performance of the 2019 European League Against
Rheumatism/American College of Rheumatology classification criteria for
systemic lupus erythematosus in a multiethnic Malaysian cohort. Int J Rheum
Dis. 2021;25(2):131-139.
38. Ruperto N, Hanrahan LM, Alarcón GS, et al. International consensus for a
definition of disease flare in lupus. Lupus. 2011;20(5):453-462.
39. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women
with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550-2558.
40. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease
activity index 2000. J Rheumatol. 2002;29(2):288-291.
41. van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of
remission in SLE: final recommendations from an international task force. Lupus
Sci Med. 2021;8(1):e000538.
42. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus
Low Disease Activity State (LLDAS). Ann Rheum Dis. 2015;75(9):1615-1621.
43. Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: diagnosis,
risk factors and preventive strategies. Mediterr J Rheumatol. 2017;28(1):4-12.
44. Szczęch J, Samotij D, Werth VP, et al. Trigger factors of cutaneous lupus
erythematosus: a review of current literature. Lupus. 2017;26(8):791-807.
45. Barbhaiya M, Costenbader KH. Ultraviolet radiation and systemic lupus
erythematosus. Lupus. 2014;23(6):588-595.
46. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College
of Rheumatology Guideline for the Management of Reproductive Health in
Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020;72(4):529-
556.
47. Keeling SO, Vandermeer B, Medina J, et al. Measuring Disease Activity and
Damage with Validated Metrics: A Systematic Review on Mortality and Damage
in Systemic Lupus Erythematosus. J Rheumatol. 2018;45(10):1448-1461.
48. Murimi-Worstell IB, Lin DH, Nab H, et al. Association between organ damage
and mortality in systemic lupus erythematosus: a systematic review and meta-
analysis. BMJ Open. 2020;10(5):e031850.
49. Campar A, Farinha F, Vasconcelos C. Refractory disease in systemic lupus
erythematosus. Autoimmun Rev. 2011;10(11):685-692.
50. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR
recommendations for the management of systemic lupus erythematosus. Ann
Rheum Dis. 2019;78(6):736-745.
51. Fairley JL, Oon S, Saracino AM, et al. Management of cutaneous manifestations
of lupus erythematosus: A systematic review. Semin Arthritis Rheum.
2019;50(1):95-127.
52. Xie X, Song Y, Yang H, et al. Effects of transitional care on self-care, readmission
rates, and quality of life in adult patients with systemic lupus erythematosus: a
randomized controlled trial. Arthritis Res Ther. 2018;20(1):184.
53. Fangtham M, Kasturi S, Bannuru RR, et al. Non-pharmacologic therapies for
systemic lupus erythematosus. Lupus. 2019;28(6):703-712.
54. Frade S, O’Neill S, Greene D, et al. Exercise as adjunctive therapy for systemic
lupus erythematosus. Cochrane Database Syst Rev. 2023;4(4):CD014816.
55. Ratanasiripong NT, Cahill S, Crane C, et al. The Outcomes of an e-Wellness
Program for Lupus Patients in Thailand: A Participatory Action Research
Approach. J Prev Med Public Health. 2023;56(2):154-163.
56. Mosca M, Tani C, Carli L, et al. Glucocorticoids in systemic lupus erythematosus.
Clin Exp Rheumatol. 2011;29(5 Suppl 68):S126-S129.

48